Previsioni

Il prezzo obiettivo medio degli analisti è +8,58€ (+517,27%). La mediana è +8,58€ (+517,27%).

Acquista	3
Mantieni	1
Vendi	0

Notizie Vai al feed delle notizie

Imunon beats Q2 forecast, stock remains under pressure over financing and clinical risks

Imunon reported an adjusted loss of $0.54 per share in the second quarter versus an expected $0.93, and disclosed no revenue. The company had $6.9 million in cash as of June 30 and completed up to $10 million in financing in June, which management says should fund operations through the end of 2026. Recruitment for the pivotal Phase III trial OVATION 3 is progressing faster than planned; the primary analysis is targeted for the first half of 2029. Despite the stronger results, the stock remains near its 52‑week low as investors weigh capital requirements, clinical uncertainties and the risk of further financing rounds. » Altro su de.investing.com
IMUNON accelerates patient recruitment in phase‑3 ovarian cancer trial

IMUNON reports a higher recruitment rate for the phase‑3 OVATION 3 study: about 0.5 patients per site per month versus the planned 0.3 and an industry average of roughly 0.2. More than 70% of sites are meeting or exceeding the assumed rate; recruitment is expected to finish in Q2 2029. The study evaluates intraperitoneally administered IMNN‑001 (100 mg/m²) added to neoadjuvant and adjuvant standard chemotherapy versus chemotherapy alone; the primary endpoint is overall survival. IMNN‑001 showed a favorable safety profile with no observed cytokine release syndromes or serious immune‑mediated events; two planned interim analyses allow for an early BLA submission if prespecified thresholds are met. » Altro su de.investing.com
Imunon secures $10 million for phase-3 ovarian cancer trial

Imunon has completed financing agreements totaling $10 million, consisting of 250 non-convertible preferred shares ($2.5 million) and two secured promissory notes ($7.72 million) bearing interest of 8% and 5% with an 18-month term. The funds are intended to support patient recruitment for the approval‑relevant phase‑3 trial OVATION 3 with IMNN‑001 in newly diagnosed, advanced ovarian cancer. Updated phase‑2 data showed an increase in median overall survival from 11.1 to 14.7 months; with additional PARP inhibitor therapy, an extension of 24.2 months over standard chemotherapy was observed. In premarket trading, Imunon shares rose about 3.3%; the company emphasizes the structure minimizes dilution since warrants were not issued. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Imunon Inc. ha registrato ricavi pari a 0,00€ e un utile netto di −2,47M€

(EUR)	giu 2026	YoY
Ricavi	0,00	-
Utile lordo	0,00	100,00%
Utile netto	−2,47M	6,05%
EBITDA	−2,34M	6,92%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+5,88M€
Numero di azioni	4,20M
Massimo/minimo a 52 settimane	+5,48€ - +1,26€
Dividendi	No
Beta	1,97
Rapporto P/E	−0,36
Rapporto PEG	0,00
Rapporto P/B	+2,04
Rapporto P/S	0,00

Profilo aziendale

Imunon, Inc. ist ein Biotechnologieunternehmen in der klinischen Phase und konzentriert sich auf die Entwicklung und Vermarktung von DNA-basierten Immuntherapien, Impfstoffen und gezielten Chemotherapien. Die Produktpipeline des Unternehmens umfasst GEN-1, eine DNA-basierte Immuntherapie für die lokale Behandlung von Eierstockkrebs, und ThermoDox, eine patentrechtlich geschützte hitzeaktivierte liposomale Verkapselung von Doxorubicin, die sich in der Entwicklungsphase für verschiedene Krebsindikationen befindet. Das Unternehmen verfügt außerdem über zwei Plattformtechnologien für die Entwicklung von Immuntherapien auf Nukleinsäurebasis, Impfstoffen und anderen DNA- oder RNA-Therapien gegen Krebs, die sich im Stadium der Machbarkeit befinden. Das Unternehmen war früher unter dem Namen Celsion Corporation bekannt und änderte im September 2022 seinen Namen in Imunon, Inc. Imunon, Inc. wurde 1982 gegründet und hat seinen Sitz in Lawrenceville, New Jersey.